Biodexa Pharmaceuticals Appoints Fiona Sharp as Chief Financial Officer and Director
Summary
Biodexa Pharmaceuticals Plc has appointed Fiona Sharp, previously Group Financial Controller, as its new Chief Financial Officer and a member of the Board of Directors, effective January 5, 2026.
Key Events
-
New Chief Financial Officer Appointed
Fiona Sharp has been appointed as the Company's Chief Financial Officer and Corporate Secretary, effective January 5, 2026.
-
Joins Board of Directors
Ms. Sharp will also serve as a member of the Board of Directors.
-
Internal Promotion
Ms. Sharp previously served as Group Financial Controller of the Company since December 2019, indicating a seamless transition.
-
Leadership Restructuring
Stephen Stamp, who previously held the CFO and Corporate Secretary roles, will continue as Chief Executive Officer.
Analysis
Biodexa Pharmaceuticals Plc has strengthened its executive leadership by appointing Fiona Sharp as Chief Financial Officer and Corporate Secretary, who will also join the Board of Directors. Ms. Sharp's internal promotion from Group Financial Controller, a role she held since 2019, signals continuity and a smooth transition in financial oversight. This move is particularly important for a micro-cap company, as it solidifies financial governance and provides dedicated leadership for critical financial operations, while the former CFO, Stephen Stamp, remains as CEO.
At the time of this filing, BDRX was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $2.22 to $92.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.